Skip to main content
Premium Trial:

Request an Annual Quote

SurroMed and Fidelity Biosciences in Research Agreement

NEW YORK, Feb. 10 - Fidelity Biosciences Group, a division of Fidelity Investments, is providing SurroMed with an undisclosed amount of funding to discover and develop biomarkers and diagnostic products for neurodegenerative conditions, the companies said today.


Under the multi-year agreement, SurroMed will analyze preclinical and clinical samples using its proprietary protein analysis platform.


SurroMed will share in the commercialization of any resulting biomarkers. Further financial terms were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.